On #WorldThyroidDay , we celebrate the strides made in personalizing diagnosis and treatment for thyroid nodules. Veracyte is committed to empowering clinicians with comprehensive insights to make more accurate treatment decisions & helping patients navigate their diagnosis.

New data from 3 studies, to be presented at #ENDO2024 in June, will demonstrate the power of Veracyte's Afirma GRID tool to help unlock new molecular insights into thyroid tumors, which may ultimately help to further personalize treatment of the disease. bit.ly/4avgJT3

Reflecting on the #AUA2024 , we were inspired by innovations in #prostatecancer care through molecular diagnostics. Dr. Phillip G. Febbo, our CSO & CMO, shares insights on this evolution and the importance of making these advancements accessible to all. #HealthEquity

Exciting news for #womenshealth : The UK's NICE expanded its recommended use of Veracyte's Prosigna Breast Cancer Assay to include patients whose #BreastCancer has spread to the lymph nodes. Check out this post to learn more, or if you're at #ESMOBreast24 , stop by booth #17!

Day 1 done at #ESMOBreast24 ! Thank you to everyone who stopped by our booth today to meet with our team and learn more about #Prosigna - THE TEST to answer more than one question for #BreastCancer patients. If you are at the conference, be sure to stop by booth #17.

We're headed to Berlin for #ESMOBreast24 ! Beginning tomorrow through May 17, visit our team at booth #17 to learn more about the #Prosigna ® Breast Cancer Assay, the #BreastCancer risk of recurrence test that confidently guides treatment decisions. prosigna.com/contact-us/

Veracyte today released our full financial results for the first quarter of 2024. Details can be found in our press release: investor.veracyte.com/news-releases/…

New data from 14 presentations at #AUA2024 show the ability of Veracyte's Decipher tests' to help personalize care for patients with #ProstateCancer and #BladderCancer , and advance disease understanding through the Decipher GRID. Learn more: investor.veracyte.com/news-releases/…

We are proud to announce that Veracyte, Inc.'s #Decipher products will be featured in five posters and presentations at #AUA24 today. If you are here, be sure not to miss these sessions.

New data in JCO Precision Oncology show that Veracyte's Decipher Prostate Test is a predictor of disease progression among patients undergoing active surveillance. Learn more about the study & how it is an example of the Veracyte Diagnostics Platform in action: investor.veracyte.com/news-releases/…

Today at #AAES2024 : Dr. Joshua Klopper, Veracyte's Medical Director of Endocrinology, will discuss how Afirma's whole-exome molecular analysis provides accurate & reproducible results to help in thyroid nodule management, & represents a platform for novel research opportunities.

Attending #AAES2024 ? Stop by booth #300-302 and meet Veracyte’s Afirma team! We look forward to meeting with you and discussing our Afirma® Genomic Sequencing Classifier, which can help confidently guide thyroid nodule treatment. See you there! #Endocrinology

Happy #LabWeek2024 ! We’re grateful to the incredible lab professionals who play a vital role in supporting Veracyte’s vision to transform cancer care for patients all over the world. Pictured here are highlights from our Day 1 celebrations - stay tuned for more updates!

Veracyte today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at #AUA2024 . Learn more about these studies in our press release: investor.veracyte.com/news-releases/… #ProstateCancer #BladderCancer

Veracyte is thrilled to advance to Round 2 of the American Society for Clinical Pathology’s #LabWeek2024 video contest! Vote daily until this Friday to show your support for our amazing lab teams across Austin, Marseille, San Diego, and South San Francisco woobox.com/nfy6wx/gallery…

Meet our team at #AACR24 (booth 623) as we showcase our cutting-edge services designed to meet our partners’ global needs for their drug development programs, from biomarker discovery to diagnostic applications. page.haliodx.com/ask-for-an-app…

The Lancet Commission projects that new #prostatecancer cases will more than double worldwide between 2020 (1.4M) and 2040 (2.9M), due to demographic and life expectancy changes, and advises that governments prepare strategies to deal with it. #Decipher bit.ly/3J9DWz8

Veracyte is at #AACR24 ! If you're attending the conference, be sure to stop by booth #623 to meet with our team. We look forward to connecting with you in San Diego!

Vote now for Veracyte in Round 1 of the American Society for Clinical Pathology’s #LabWeek2024 video contest! Show your support for our amazing lab teams who put together this video showcasing life in the lab, and some pretty impressive dance moves. bit.ly/4an9YDu

In celebration of #IWD , Veracyte Women's Leadership hosted a fireside chat with Ryen MacDonald and Katrina Nashashibi, where they discussed career growth, persevering through challenges, mentorship, and much more. Thank you Ryen, Katrina, & the VWL team for this inspiring event!